Christopher J. Burns

The Walter and Eliza Hall Institute of Medical Research provides medical research services. It undertakes research in a range of areas, preventing and treating diseases including breast, ovarian and blood cancers, type 1 diabetes, rheumatoid arthritis, coeliac disease and malaria. The firm’s research areas include bioinformatics, cancer biology, cell death, cell signaling, clinical translation, epigenetics, genomics, immunology, and inflammation and vaccine development. The company was founded in 1915 and is headquartered in Melbourne, Australia.

Diversa Pty Ltd. engages in the provision of investment management and financial services. It operates through Superannuation Services and Trustee Services segments. The Superannuation Services segment provides administration and promotion services to superannuation funds and the issue of group risk products. The Trustee Services segment involves in the third party superannuation trustee services and investment services. The company was founded by Matthew Morgan and Angus Craig on July 03, 1997 and is headquartered in Melbourne, Australia.

Part of Gilead Sciences, Inc., YM BioSciences Australia Pty Ltd. develops cancer treatment pharmaceuticals. The private company is based in Melbourne, Australia.

Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI.

MetabloQ Pty Ltd. develops drugs for cancer treatment. It treats triple-negative breast cancer, prostate cancer and melanoma cancer diseases. The company was founded in 2016 and is headquartered in Melbourne, Australia.